Announcements Trials
Browse Landscape

Phase

Phase 2 33Phase 1 7Phase 3 6Phase NA 5Phase 2/3 1

Status

Completed 2Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

OTHER 4OTHER_GOV 1NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Lymphoma 35Leukemia 34Small Cell Lung Carcinoma 33Leukemia, Myeloid, Acute 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Lung Neoplasms 24Lymphoma, Large B-Cell, Diffuse 19Neuroblastoma 15Lymphoma, Non-Hodgkin 15Carcinoma, Non-Small-Cell Lung 14Leukemia, Erythroblastic, Acute 13Hodgkin Disease 13Leukemia, Myelomonocytic, Acute 12Leukemia, Monocytic, Acute 12Leukemia, Megakaryoblastic, Acute 12Sarcoma 11Lymphoma, Follicular 10Burkitt Lymphoma 10Lymphoma, Large-Cell, Immunoblastic 9Testicular Neoplasms 7Teratoma 7Myelodysplastic Syndromes 7Congenital Abnormalities 7Multiple Myeloma 6Endodermal Sinus Tumor 6Anemia, Refractory, with Excess of Blasts 6Testicular Germ Cell Tumor 5Ovarian Neoplasms 5Neuroectodermal Tumors, Primitive, Peripheral 5Central Nervous System Neoplasms 5

Interventions

Dexamethasone 168Bortezomib 90Lenalidomide 85Thalidomide 44daratumumab 43pomalidomide 42Melphalan 39Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 12ixazomib 11isatuximab 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5Radiotherapy 4Mycophenolic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × Etoposide × Clear all
NCT00734877 2026-05-22

TT4B

University of Arkansas

Phase 3 Active not recruiting
382 enrolled
Plasma cell

Multiple Myeloma

NCT00572169 2026-02-05

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

University of Arkansas

Phase 3 Active not recruiting
177 enrolled
Plasma cell

Multiple Myeloma

NCT06520176 2024-07-25

Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

The Affiliated People's Hospital of Ningbo University

Phase 3 Recruiting
99 enrolled
Plasma cell

Multiple Myeloma

NCT00083915 2017-11-20

DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation

University of Arkansas

Phase 3 Completed
97 enrolled 7 charts
Plasma cell

Multiple Myeloma

NCT00083551 2015-11-23

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

University of Arkansas

Phase 3 Completed
668 enrolled 7 charts
Plasma cell

Multiple Myeloma, Neoplasms

NCT00005834 2015-03-06

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

SWOG Cancer Research Network

Phase 3 Terminated
19 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡